<DOC>
	<DOC>NCT02829957</DOC>
	<brief_summary>A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.</brief_summary>
	<brief_title>RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Nonpregnant women, age 1850, Objectively diagnosed VTE or atrial fibrillation within the previous 30 days, and no menstrual cycle since diagnosis Patient reported active menstruation, requiring &gt;3 menstrual periods in the previous 6 months Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or longer Patients must have a working mobile phone Package insert exclusions for Eliquis (Apixaban) or Xarelto (Rivaroxaban): [active pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g., anaphylactic reactions)] Plan to become pregnant in the next three months. Concomitant prescribed use of aspirin or thienopyridine or other platelet inhibiting drugs Plan for surgical hysterectomy or endometrial ablation Known uterine cancer Von Willebrand's disease, or hemophilia Known coagulopathy from liver disease Conditions likely to preclude adherence to study procedures: Active intravenous drug use, known alcoholism, homelessness, or uncontrolled psychiatric illness.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>